TWA
CAPR icon

TCI Wealth Advisors’s Capricor Therapeutics CAPR Stock Holding History

TCI Wealth Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed – – 1538
2020
Q2 		$0 Buy
+100
New +$436 ﹤0.01% 1476

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

TCI Wealth Advisors's CAPR Position: Q3 2020 in Review

TCI Wealth Advisors sold out of Capricor Therapeutics (CAPR) in Q3 2020, closing a stake of 100 shares.

TCI Wealth Advisors first reported a position in CAPR in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 25 funds tracked by Wall St. Rank hold CAPR as of Q3 2020.

  • TCI Wealth Advisors reported no remaining Capricor Therapeutics position as of Q3 2020 after selling out during the quarter.
  • TCI Wealth Advisors sold 100 Capricor Therapeutics shares in Q3 2020.
  • TCI Wealth Advisors first reported a position in Capricor Therapeutics in Q2 2020 and held it in 1 quarter.
  • TCI Wealth Advisors's Capricor Therapeutics position peaked at $0 in Q2 2020.
  • 25 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2020.

Based on TCI Wealth Advisors's 13F filing for Q3 2020, filed 20 Oct 2020.